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Abstract
Background: Drug shortages and increasing generic drug prices are associated with low levels of competition.
Mergers and acquisitions impact the level of competition. Record merger and acquisition activity was reported for
the pharmaceutical sector in 2014/15, yet information on mergers and acquisitions in the generic drug sector are
absent from the literature. This information is necessary to understand if and how such mergers and acquisitions
can be a factor in drug shortages and increasing prices.
Methods: Data on completed merger and acquisition deals that had a generic drug company being taken over
(i.e. ‘target’) were extracted from Bloomberg Finance L.P. The number and announced value of deals are presented
globally, for the United States, and globally excluding the United States annually from 1995 to 2016 in United
States dollars.
Results: Generic drug companies comprised 9.3% of the value of all deals with pharmaceutical targets occurring
from 1995 to 2016. Globally, in 1995 there were no deals, in 2014 there were 22 deals worth $1.86 billion, in 2015
there were 34 deals totalling $33.56 billion, and in 2016 there were 42 deals worth in excess of $44 billion. This
substantial increase was partially attributed to Teva’s 2016 acquisition of Allergan’s generic drug business. The surge
in mergers and acquisitions for 2015/16 was driven by deals in the United States, where they represented 89.7% of
the dollar value of deals in those years.
Conclusions: The recent blitz in mergers and acquisitions signals that the generic drug industry is undergoing a
transformation, especially in the United States. This restructuring can negatively affect the level of competition that
might impact prices and shortages for some products, emphasizing the importance of updating regulations and
procurement policies.
Keywords: Pharmaceuticals, Generics, Drugs, Mergers, Acquisitions, Shortages, Pricing
Background
In the wake of expired patents and the introduction of
biosimilars, the $61 billion generic drug manufacturing
industry in the United States is expected to continue
growing [1]. Generic drugs (including biosimilars)
accounted for 89% in the United States of all dispensed
prescription drugs in 2016, up from 72% in 2008 and
43% in 1996 [2]. Since generic drugs are priced lower
than their branded counterparts, they generate cost
savings for individuals and drug plans [1, 3].
Record numbers of mergers and acquisitions in the
pharmaceutical industry were reported for the years
2014 and 2015, based on the announcement date of the
deals [4, 5]. The literature has cited several potential
reasons for pharmaceutical companies pursuing mergers
and acquisitions. They include: achieving economies of
scale and scope, gaining corporate control, acquiring
specific assets such as patents, and buying out dying or
financially weak companies [1, 6]. The literature on
mergers and acquisitions has typically focused on the
brand-name pharmaceutical sector and the relationship
between mergers and acquisitions and research and de-
velopment or productivity [7–10], which is not relevant
to understanding the dynamics in the generic drug sec-
tor. In the case of generics, we find little literature on
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the causes, impacts, and magnitude of mergers and ac-
quisitions in that sector.
Mergers and acquisitions in the generic sector are
often considered a business decision to increase effi-
ciency gains [4]. However, studies analyzing increasing
prices of generics and drug shortages have observed
that mergers and acquisitions were often a factor
associated with significant price increases, drug short-
ages, supply disruption, and a reduced number of
competing manufacturers [3, 11–17]. Increasing
generic drug prices and drug shortages have become
pressing issues particularly in the United States [2, 13].
Before 2013, price increases for generic drugs were less
significant in the United States, while since 2013 changes
in these drugs’ prices substantially increased overall drug
spending [14]. According to a 2014 study by the Drugs
Channel Institute and Pembroke Consulting, the price of
half of the generic drugs available in the United States
increased from the previous 12 months [3]. A study of
1120 generic drugs demonstrated that drugs with fewer
suppliers were more likely to be associated with price
increases. Generics with a duopoly, near-monopoly, and
monopoly were associated with price increases of
29%, 59% and 116% respectively between 2008 and
2013 as compared to drugs with the highest level of
competition [17]. While increases in generic drug
prices and shortages are related to market competi-
tion levels, mergers and acquisitions carry the risk of
decreasing competition [16, 17].
The few studies on merger and acquisition activity in
the pharmaceutical drug sector over time provide little
information on the most recent trends in terms of the
volume or geographic breakdown of this activity and
provide no clear presentation of the methods used to
analyze the trends [18, 19]. Additionally, because the
impact of mergers and acquisitions can be observed after
their completion and not at the time of the announce-
ment, it is important to compile mergers and acquisi-
tions based on the completion date, which has not been
done previously for the generic drug sector. As reports
indicate that 2014 and 2015 were landmark years in
terms of mergers and acquisitions involving pharmaceut-
ical companies (based on the date of the deals’ an-
nouncement), further investigation into the extent of
merger and acquisition activity in the generic sector will
provide important information on its present state and
indications of its future directions. This study measures
the magnitude of mergers and acquisitions in the generic
pharmaceutical sector in the United States and abroad
from 1995 to 2016.
Methods
To study merger and acquisition deals in the generic
drug sector, we examined the number and size of
completed deals over time that had a target firm (i.e.
firm being taken over) classified as a generic medical
drug company. We focused on completed deals, rather
than pending or proposed ones, because the potential
impacts of the deal start to come to fruition after com-
pletion. To identify the largest mergers and acquisitions
that might have impacted the data for specific years, the
ten largest deals in terms of the announced dollar value
were reported.
Data
Bloomberg Finance L.P. was used to identify and collect
information on mergers and acquisitions in the pharma-
ceutical sector. Bloomberg L.P. terminal is a financial
software that assembles real-time data on markets. To
obtain information on mergers and acquisitions in the
generic medical drug sector, ‘MA’ was searched and the
data were filtered by select attributes. Deals included in
the analysis were: classified as a merger and/or acquisi-
tion, and had a target firm classified as a medical drug –
generic sector firm, and were considered completed
deals. Results for generic targets based in any region
(referred to as global) were compiled according to the
deals’ completion date for each year from January 1st,
1995 to December 31st, 2016. This process was repeated
with generic targets based in the United States and then
with global deals excluding the United States. Figure 1
demonstrates how the data were selected.
Not all firms publically release the announced value
paid to acquire another firm. Specifically, when private
companies are acquired, the value and other financial
terms of the deal do not have to be disclosed. Larger
companies are often public companies and are required
Mergers and acquisitions with global 
pharmaceutical targets completed from 
1995 to 2016
7,011 deals
$2,575.73 billion
Mergers and acquisitions  with global 
generic targets completed from 1995 to 
2016
379 deals
$254.99 billion
Completed mergers and acquisitions with 
global generic targets completed from 
1995 to 2016
345 deals
$160.30 billion
Excluded mergers and acquisitions with 
global generic targets completed from 
1995 to 2016, with deals that were:
Terminated: 17 deals, $42.85 billion
Withdrawn: 10 deals, $51.73 billion
Pending: 7 deals, $0.11 billion
Fig. 1 Flowchart of how study sample was selected. Dollar values
are in United States dollars and represent the total announced value
of merger and acquisition deals
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to disclose the financial terms of the merger and acquisi-
tion deal. As a result, some deals do not have an
announced dollar value available and are only repre-
sented in the number of deals. All figures are presented
in United States dollars and were not adjusted for
inflation.
Analysis
To summarize the data, line graphs display the number
of deals and total announced value for each year from
1995 to 2016. The number of deals reflects both those
with released and private announced values. The top ten
deals in terms of highest announced value over the
21 years under study are tabulated.
Results
The final study sample consisted of 345 deals totalling
$160.30 billion in value (Fig. 1). Globally, merger and ac-
quisition deals from 1995 to 2016 with generic drug
targets represented 9.3% of the total value of mergers
and acquisitions with pharmaceutical targets (Table 1).
From 1995 to 2016 combined, generic targets in the
United States made up the majority (63.5%) of the value
of deals with generic targets.
In 1995, the total value of mergers and acquisitions
with generic targets was negligible, and in 2016 the an-
nual value was $44.01 billion, representing 34.9% of all
mergers and acquisitions in the pharmaceutical sector.
While the number of deals had substantially increased
since 2000, the total announced value of the deals in-
creased even more (Figs. 2 and 3). There were 158, 54,
and 104 completed deals without available announced
values for global, United States and global excluding
United States regions respectively (data not shown).
Table 2 provides a list of the 10 largest merger and ac-
quisition deals with generic targets by dollar amount.
The increase in value from 2014 to 2016 is partially ex-
plained by a higher volume of deals, but one deal in par-
ticular, Teva’s acquisition of Allergan’s generic drug
business, represented 89.9% of the total value for 2016.
Discussion
Prior to the year 2000, mergers and acquisitions played a
minimal role in the generic drug sector. The growth in
mergers and acquisitions afterward is consistent with in-
dustry reports noting that generic firms have expanded
their operations through mergers and acquisitions in re-
cent years [1, 18]. Our analysis confirms that 2015 and
2016 in particular experienced record levels of merger
and acquisition activity in the generic drug industry,
based on the date of deal completion. Our results sug-
gest that there is a substantial movement in the last two
years in the generic sector towards using merger and ac-
quisition deals to grow rather than traditional greenfield
investments. The identification of the largest mergers
and acquisitions show that since 2011, three acquisitions
were announced at more than $10 billion, suggesting
that larger companies are being acquired.
The literature provides some explanations for the re-
cent proliferation of merger and acquisition deals in the
pharmaceutical industry [1, 4–6]; they include: 1 – gen-
eric firms can benefit from economies of scale through
savings on administrative and capital costs; 2 – the loss
of major patents have brought brand-name manufac-
turers to enter the generic drug market; 3 – mergers and
acquisitions may be pursued as a way to enter emerging
markets faster; 4 – loans can be obtained easily due to
low-interest rates and because banks consider the
Table 1 Total announced value of merger and acquisition deals with pharmaceutical and generic drug targets a,b,c
Sector Global United States Global excluding the United States
All pharmaceuticals from 1995 to 2016 (in billions) $1717.69 $1035.57 $682.12
Generics from 1995 to 2016 $160.30 $101.71 $58.59
Generics as % of total 9.3% 9.8% 8.6%
All pharmaceuticals 2014 $105.14 $64.92 $40.22
2015 $250.32 $191.20 $59.12
2016 $126.28 $97.43 $28.85
Generics 2014 $1.86 $0.89 $0.97
2015 $33.56 $26.66 $6.90
2016 $44.01 $42.95 $1.06
Generics as % of all pharmaceuticals 2014 1.8% 1.4% 2.4%
2015 13.4% 14.0% 11.6%
2016 34.9% 44.1% 3.7%
aData were gathered from Bloomberg L.P. Finance
bIncluded completed deals with a generic target
cFigures are in billions of United States dollars and were not adjusted for inflation
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1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Global 0 1 1 1 2 5 9 8 12 20 22 17 28 28 17 18 23 15 20 22 34 42
U.S. 0 1 1 1 1 2 3 2 5 9 11 5 7 6 6 5 7 4 6 7 16 17
Excluding U.S. 0 0 0 0 1 3 6 6 7 11 11 12 21 22 11 13 16 11 14 15 18 25
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Fig. 2 Number of completed merger and acquisition deals with generic targets from 1995 to 2016. Data were gathered from Bloomberg Finance
L.P. The number of deals included deals that did not release the announced value
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Global 0.00 0.36 0.00 0.10 0.66 0.98 0.99 1.14 0.06 1.43 10.27 7.93 16.20 11.23 3.24 1.81 15.62 7.98 0.86 1.86 33.56 44.01
U.S. 0.00 0.36 0.00 0.10 0.21 0.91 0.15 0.00 0.00 0.65 4.19 7.62 1.86 10.48 0.01 1.25 1.11 2.24 0.07 0.89 26.66 42.95
Excluding U.S. 0.00 0.00 0.00 0.00 0.45 0.07 0.84 1.14 0.06 0.78 6.08 0.30 14.34 0.75 3.23 0.56 14.51 5.75 0.80 0.97 6.90 1.06
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Global U.S. Excluding U.S.
Fig. 3 Total announced value of completed deals with generic targets from 1995 to 2016. Data were gathered from Bloomberg Finance L.P.
terminal. Financial figures are in billions of United States dollars not adjusted for inflation and rounded to two decimal places
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healthcare sector as more reliable; 5 – investors’ pres-
sure to create shareholder value and pressure; 6 – fear
of ‘missing out’, where all the good assets are being
bought out; 7 – vertical integration to buy parts or sec-
tions of the supply chain; 8 – the emergence of biosimi-
lars also created new market niches for more complex
products with better market exclusivity, thereby creating
more appealing targets for mergers and acquisitions (in
the United States, new biosimilars are granted 12 years
of market exclusivity, compared to 180 days given to
traditional generic drugs entering the market).
With the recent wave of mergers and acquisitions, it
appears that the industry is consolidating; however, the
number of enterprises in this industry grew from 2010
to 2015 [1]. Despite the appearance of consolidation, the
top four generic pharmaceutical manufacturing firms in
the United States made only 26.4% of the industry’s total
revenue in 2015 [1]. The largest generic company, Pfizer
Global Established Products, represented 9% of the glo-
bal market value for generics and the top ten global
companies represented less than 40% of global market
value [19]. The Herfindahl-Hirschman index (HHI), a
commonly accepted measure of market concentration,
was estimated at 0.021 for the global generic sector in
February 2016, way below the United States Department
of Justice threshold of 0.25 where caution starts to be
exercised by antitrust authorities [19]. However, the low
overall concentration ratio might be misleading as com-
pared to concentration index for specific therapeutic cat-
egories or molecules. For instance, a study that analyzed
1200 generic drugs showed that nearly half of the drugs
had an HHI value exceeding 0.5, which is considered du-
opoly like competition level [17]. The study also showed
that increases in generic drug prices in the United States
are strongly related with market competition levels. In
fact, several companies developed a novel business
model based on the domination on non-competitive
markets for older drugs by cornering niche generic mar-
kets through mergers and acquisitions in order to sub-
stantially increase prices [20]. Mergers and acquisitions
were thus an important factor to explain the large price
increases for different generics like albendazole (treat-
ment for intestinal parasites), dextroamphetamine (treat-
ment for attention-deficit disorder), and pyrimethamine
(treatment for toxoplamosis), nitroprusside (treatment
for high blood pressure) and isoprotenerol (used in
cardiac emergencies) [11, 13, 20].
Our results show that merger and acquisition activity
among generic drug companies have become a major
trend in this industry since 2004, but that this trend has
accelerated in 2015 and 2016, and that the United States
target companies have been the center of this acceler-
ation. It is important to note that the record level of
mergers and acquisitions in the United States appeared
after two years of price increases for a large proportion
of generics in the country [3]. Mergers and acquisitions
should not be considered the root cause of generic drug
price increases, but rather as a factor exacerbating the
trend of rising prices. The results also show that the
focus on United States generic targets in the last few
years is not linked to the need to enter emerging
markets or vertical integration with manufacturers of
raw ingredients in emerging countries. The significant
price increase for many generic drug products in the
United States also means that mergers and acquisitions are
not simply a means to increase efficiency and reduce costs.
While there was a “patent cliff” starting in 2010 when
many blockbuster brand-name products lost their patent
protection, greatly increasing the market for generics,
many governments also imposed measures like generic
Table 2 10 largest global deals with generic targets from 1995 to 2016 a,b,c
Target Acquirer Announced value
(in billions)
Announced date Completion date
Allergan’s generic drug business Teva Pharmaceutical Industries Ltd 39.56 27 July 2015 2 August 2016
Hospira Inc Pfizer Inc 16.81 5 February 2015 3 September 2015
Nycomed A/S Takeda Pharmaceutical Co Ltd 13.73 19 May 2011 30 September 2011
Barr Pharmaceuticals Inc Teva Pharmaceutical Industries Ltd 8.83 18 July 2008 23 December 2008
Par Pharmaceutical Holdings Inc Endo International PLC 8.09 18 May 2015 28 September 2015
IVAX Corp Teva Pharmaceutical Industries Ltd 7.58 25 July 2005 26 January 2006
Merck Generics Mylan NV 6.62 12 May 2007 2 October 2007
Hexal AG Novartis AG 5.69 21 February 2005 7 June 2005
Actavis Group HF Allergan plc 5.61 25 April 2012 31 October 2012
Developed markets branded
generics pharmaceuticals
Mylan NV 5.61 14 July 2014 27 February 2015
aData were gathered from Bloomberg L.P. Finance
bIncluded completed deals with a generic target
cFinancial figures are in billions of United States dollars not adjusted for inflation and rounded to two decimal places
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substitution, heightening the demand for generics
[15–19, 21]. Governments and private drug plans have
also imposed downward pressure on the price of generic
drugs, forcing a restructuring in some parts of the in-
dustry [22]. This downward price pressure from large
buyers is problematic for smaller manufacturers, creat-
ing incentives for mergers and acquisitions among
sellers to adjust to the market factors [23].
Typically, mergers and acquisitions reduce the number
of manufacturers for specific drugs in some therapeutic
niches, which can potentially lead to price increases.
Mergers and acquisitions are also identified as a poten-
tial cause for drug shortages since they may result in
supply disruptions based on business decisions to nar-
row the focus of the product line, discontinue products
or to shift manufacturing to another facility [16]. For
example, after acquiring the largest producer of generic
injectable drugs in 2015, Hospira, Pfizer became the only
supplier of injectable sodium bicarbonate in Canada
[24]. The drug, similar to baking soda, is widely used for
emergency procedures, open heart surgery or during
some chemotherapy treatment. After manufacturing
problems, and because of a lack of alternative manufac-
turers, Canada had a shortage of the drug in 2017 [24].
The record level of mergers and acquisitions in the last
two years indicate that the economic structures of the
generic sector are shifting, especially in the United
States. In this context of increasing economic restructur-
ing, countries must adapt their regulations and procure-
ment policies accordingly in order to protect themselves
against abusive price increases or drug shortages. The
market forces in the generic sector do not necessarily
ensure lower prices and safe supply for all generics.
Governments must thus develop institutional capacities
to deal with potential problems.
Governments should consider implementing for their
public drug plan a procurement process with tenders that
include specific clauses to ensure the safety of the drug
supply and reduce drug shortages [25, 26]. The establish-
ment of a public generic manufacturer, like what is found
in Sweden, could also be explored as a way to deter preda-
tory pricing and reduce drug shortages [15, 24, 25]. Anti-
trust authorities should also examine the current practices
of generic manufacturers in this context of merger mania.
In particular, in the United States, the antitrust laws pro-
tect consumers only against anticompetitive strategies
such as price fixing among competitors. Generic manufac-
turers that legally obtain a monopoly on a product
through mergers and acquisitions are free to unilaterally
increase prices [11]. To ensure more market competition
between manufacturers, the United States Food and Drug
Administration could create special pathways for foreign
manufacturers or new competitors to promote competi-
tion and allow the market to work more efficiently [11].
Because of the magnitude of current mergers and acquisi-
tions in an evolving generic sector, solely relying on mar-
ket forces might make some essential generic drugs
inaccessible for many due to high costs or shortages.
Limitations
Although this study starts to address the lack of infor-
mation on mergers and acquisitions in the generic drug
industry, it has several limitations. The most noteworthy
limitation of this study is that we did not directly associ-
ate merger and acquisition deals with their specific out-
comes such as the price or shortages of the products
involved in the mergers. Looking at the years 2015 and
2016, it is too early to reliably determine the impacts of
the mergers and acquisitions. Another limitation was
that the announced value was “not announced” in cases
where a private company acquired the generic drug
company; the likely result is the underestimation of the
value of mergers and acquisitions.
Conclusions
This analysis traced merger and acquisition activity in the
generic drug sector from 1995, when deals were negligible,
to 2016 when the total value of deals rose to $44 billion,
representing 35% of all mergers and acquisitions among
pharmaceuticals. The surge in mergers and acquisitions
recorded for 2015 and 2016 indicates sectorial transforma-
tions, for which further research will be needed to deter-
mine the specific impacts on the availability and pricing of
generic drugs. We can only observe that the structures of
the generic market are changing. The generic drug indus-
try has changed since 1995, and it is thus necessary to
update regulations and procurement policies accordingly
to develop institutional capacities to deal with potential
problems. In particular, Antitrust authorities should
scrutinize current practices, public drug plans should
consider modifying their procurement process to ensure the
safety of drug supply, and governments could also explore
the possibility of establishing public generic manufacturers.
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